Skip to content

Translational medicine research on new patent product dysmenorrhea treatment paste

Translational medicine research on new patent product dysmenorrhea treatment paste

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000037102
Enrollment
Unknown
Registered
2020-08-26
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dysmenorrhea

Interventions

Sponsors

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
16 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Patients who meet the diagnostic criteria of Western medicine for primary dysmenorrhea; 2. TCM syndrome differentiation belongs to qi stagnation and blood stasis syndrome; 3. Patients aged 16-40 years old; 4. Patients with regular menstrual cycle (28 ± 7) days; 5. Patients who did not take analgesics, sedatives and hormonal drugs within 2 weeks before receiving this therapy; 6. Patients who sign informed consent form; 7. Patients with VAS score >= 4.

Exclusion criteria

Exclusion criteria: 1. Lactating women; 2. Patients with serious life-threatening primary diseases such as cardio cerebrovascular system, liver, kidney and hematopoietic system, as well as psychosis; 3. Patients who are participating in other clinical trials.

Design outcomes

Primary

MeasureTime frame
effective rate;

Secondary

MeasureTime frame
??? Cure rate;degree of dysmenorrhea;TCM Syndrome Scale;

Countries

China

Contacts

Public ContactZhang Chunyan

Yueyang Integrated Traditional Chinese and Western Medicine Hospital Affiliated to Shanghai University of traditional Chinese Medicine

zh_ch_yan@163.com+86 15921068889

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 26, 2026